Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The FDA has found a probable cancer-causing contaminant in generic drugs shipped from abroad––most recently, Zantac (ranitidine).
At the center of the lawsuit is Teva Pharmaceutical, slated to sell a generic version of the HIV prevention pill PrEP next year.
The head of the Food and Drug Administration cited a long commute and time away from family as reasons to step down.
Branded drugs with expired patents but without generic competition may keep prices high and ultimately hurt patients.
This focus is critical because, first and foremost, these drug products provide people with important therapies.
The FDA wants to give prescribers and patients access to the most up-to-date information to guide treatment decisions.
“The result of this progress is that we openly talk about curing cancers that were recently fatal,” says Commissioner Gottlieb.
We know that there are situations where that expected competition isn’t materializing in a timely manner.
Enhancing generic competition is an effective way to promote access to needed medicines.
Stocks of drug companies are rising—and that’s not a good sign for consumers.
Access to prescription drugs is a matter of public health.
Agency aims to enhance competition, promote access and lower drug prices.
Scott Gottlieb has said he wants lower costs and faster drug approvals.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.